Concepts (98)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Urticaria | 3 | 2020 | 472 | 1.07 | Why? |
| Photosensitivity Disorders | 2 | 2018 | 14 | 0.88 | Why? |
| Isotretinoin | 1 | 2020 | 58 | 0.81 | Why? |
| Alopecia Areata | 1 | 2020 | 140 | 0.68 | Why? |
| Ustekinumab | 1 | 2017 | 216 | 0.59 | Why? |
| Omalizumab | 1 | 2017 | 158 | 0.57 | Why? |
| Latent Tuberculosis | 1 | 2018 | 324 | 0.53 | Why? |
| Biological Therapy | 1 | 2018 | 456 | 0.52 | Why? |
| Antitubercular Agents | 1 | 2018 | 775 | 0.45 | Why? |
| Dermatologic Agents | 1 | 2017 | 489 | 0.44 | Why? |
| Autoimmunity | 1 | 2017 | 841 | 0.40 | Why? |
| Psoriasis | 3 | 2019 | 1739 | 0.39 | Why? |
| Autoantibodies | 1 | 2017 | 2094 | 0.30 | Why? |
| Tuberculosis | 2 | 2019 | 2895 | 0.29 | Why? |
| Sunlight | 2 | 2018 | 287 | 0.27 | Why? |
| Skin Diseases, Viral | 2 | 2020 | 436 | 0.27 | Why? |
| Exanthema | 2 | 2020 | 1097 | 0.21 | Why? |
| Melanoma | 2 | 2021 | 1229 | 0.20 | Why? |
| Tuberculin Test | 1 | 2019 | 141 | 0.18 | Why? |
| Somatostatin | 1 | 2018 | 49 | 0.18 | Why? |
| Octreotide | 1 | 2018 | 56 | 0.18 | Why? |
| Intestinal Neoplasms | 1 | 2018 | 42 | 0.18 | Why? |
| Antigens, Nuclear | 1 | 2017 | 32 | 0.18 | Why? |
| Lighting | 1 | 2017 | 42 | 0.17 | Why? |
| Drug Evaluation | 1 | 2017 | 100 | 0.17 | Why? |
| Histamine H1 Antagonists | 1 | 2017 | 79 | 0.16 | Why? |
| Chickenpox | 1 | 2020 | 194 | 0.16 | Why? |
| Ultraviolet Therapy | 1 | 2018 | 138 | 0.16 | Why? |
| Herpes Simplex | 1 | 2020 | 272 | 0.16 | Why? |
| Peptides, Cyclic | 1 | 2018 | 223 | 0.15 | Why? |
| Skin Neoplasms | 2 | 2021 | 1679 | 0.15 | Why? |
| Antibodies, Antinuclear | 1 | 2017 | 234 | 0.15 | Why? |
| Phototherapy | 1 | 2017 | 138 | 0.15 | Why? |
| Herpes Zoster | 1 | 2020 | 331 | 0.14 | Why? |
| Neuroendocrine Tumors | 1 | 2018 | 241 | 0.14 | Why? |
| Drug Resistance | 1 | 2017 | 395 | 0.14 | Why? |
| Hidradenitis Suppurativa | 1 | 2018 | 309 | 0.12 | Why? |
| Carcinoma, Squamous Cell | 1 | 2021 | 902 | 0.12 | Why? |
| Stomach Neoplasms | 1 | 2018 | 477 | 0.12 | Why? |
| Pancreatic Neoplasms | 1 | 2018 | 609 | 0.11 | Why? |
| T-Lymphocyte Subsets | 1 | 2018 | 1387 | 0.10 | Why? |
| Drug Monitoring | 1 | 2018 | 1408 | 0.10 | Why? |
| Skin | 1 | 2020 | 2096 | 0.09 | Why? |
| Tumor Necrosis Factor-alpha | 1 | 2018 | 2483 | 0.09 | Why? |
| Risk | 1 | 2018 | 5288 | 0.07 | Why? |
| Consensus | 1 | 2020 | 6345 | 0.07 | Why? |
| Immunity, Cellular | 1 | 2018 | 3614 | 0.07 | Why? |
| Biological Products | 1 | 2019 | 2331 | 0.07 | Why? |
| Patient Selection | 1 | 2018 | 4560 | 0.06 | Why? |
| Middle Aged | 10 | 2021 | 270681 | 0.06 | Why? |
| Longitudinal Studies | 1 | 2017 | 9893 | 0.06 | Why? |
| Prospective Studies | 4 | 2020 | 43301 | 0.06 | Why? |
| Acantholysis | 1 | 2020 | 18 | 0.05 | Why? |
| Ichthyosis | 1 | 2020 | 35 | 0.05 | Why? |
| Humans | 16 | 2021 | 930598 | 0.05 | Why? |
| Tumor Burden | 1 | 2021 | 369 | 0.05 | Why? |
| Antibodies, Monoclonal | 1 | 2018 | 8041 | 0.05 | Why? |
| Subcutaneous Tissue | 1 | 2018 | 18 | 0.05 | Why? |
| Female | 10 | 2021 | 380317 | 0.04 | Why? |
| Ultrasonography, Doppler, Color | 1 | 2018 | 107 | 0.04 | Why? |
| Spain | 3 | 2021 | 15545 | 0.04 | Why? |
| Pneumonia, Viral | 3 | 2020 | 243684 | 0.04 | Why? |
| Coronavirus Infections | 3 | 2020 | 253789 | 0.04 | Why? |
| Biopsy, Needle | 1 | 2018 | 303 | 0.04 | Why? |
| Pandemics | 4 | 2021 | 389249 | 0.04 | Why? |
| Delayed-Action Preparations | 1 | 2018 | 291 | 0.04 | Why? |
| Quality of Life | 1 | 2017 | 9820 | 0.04 | Why? |
| Drug Eruptions | 1 | 2020 | 319 | 0.04 | Why? |
| Male | 8 | 2021 | 367725 | 0.04 | Why? |
| Adult | 7 | 2021 | 244371 | 0.04 | Why? |
| Dermatologists | 1 | 2020 | 435 | 0.04 | Why? |
| Terminology as Topic | 1 | 2020 | 546 | 0.03 | Why? |
| Aged | 6 | 2021 | 215776 | 0.03 | Why? |
| Physical Examination | 1 | 2018 | 755 | 0.03 | Why? |
| Antiviral Agents | 2 | 2020 | 41703 | 0.03 | Why? |
| Immunohistochemistry | 1 | 2018 | 2275 | 0.03 | Why? |
| Young Adult | 4 | 2021 | 93724 | 0.02 | Why? |
| Cross-Sectional Studies | 3 | 2021 | 53120 | 0.02 | Why? |
| Betacoronavirus | 3 | 2020 | 204454 | 0.02 | Why? |
| Prognosis | 2 | 2021 | 32490 | 0.02 | Why? |
| Aged, 80 and over | 3 | 2021 | 88759 | 0.02 | Why? |
| Adolescent | 3 | 2021 | 86841 | 0.02 | Why? |
| Patient Satisfaction | 1 | 2018 | 2517 | 0.02 | Why? |
| Chloroquine | 1 | 2020 | 3152 | 0.02 | Why? |
| Azithromycin | 1 | 2020 | 3943 | 0.02 | Why? |
| Diagnosis, Differential | 1 | 2018 | 7220 | 0.02 | Why? |
| Tertiary Care Centers | 1 | 2020 | 8248 | 0.01 | Why? |
| Risk Factors | 2 | 2021 | 71621 | 0.01 | Why? |
| Child | 2 | 2021 | 70012 | 0.01 | Why? |
| Registries | 1 | 2021 | 12327 | 0.01 | Why? |
| Host-Pathogen Interactions | 1 | 2020 | 11041 | 0.01 | Why? |
| Time Factors | 1 | 2020 | 31397 | 0.01 | Why? |
| Hydroxychloroquine | 1 | 2020 | 12447 | 0.01 | Why? |
| Retrospective Studies | 2 | 2018 | 105322 | 0.01 | Why? |
| Vaccination | 1 | 2021 | 19050 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2020 | 43792 | 0.01 | Why? |
| Communicable Disease Control | 1 | 2021 | 29620 | 0.01 | Why? |
| Tomography, X-Ray Computed | 1 | 2018 | 25144 | 0.01 | Why? |
Rodríguez-Jiménez's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(98)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(145)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_